Table 1

Ibrutinib in clinical trials for chronic lymphoid leukemia
Studies Phase Ib/II for CLL/SLL Phase Ib/II for CLL patients (N=116) [26] Ibrutinib Ibrutinib
+ +
Rituximab Ofatumumab
(High risk refractory/relapsed) Treatment naïve patients >65 years old Relapsed/refractory High risk relapsed/refractory (Relapsed/refractory CLL) (Relapsed/refractory CLL)
[N=85] [24] [N=40] [40] [N=40] [41]
ORR 71% 71% (CR=10%, PR=61%) 67 % (CR=3%, PR=64%) 50% (PR=50%, CR=0%) 85% 100%

ORR = overall response rate; CR = complete remission; PR = partial remission.

Novero et al.

Novero et al. Experimental Hematology & Oncology 2014 3:4   doi:10.1186/2162-3619-3-4

Open Data